Showing results (71-80 of 102) with videos related to
Sort By:
Pageof 11
Cancer|August 27, 2015
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancerLakshmi Nayak, Lisa M DeAngelis, H Ian Robins, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancerGerold Bepler, Charles Williams, Michael J Schell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology InteractionsLouis A Penner, John F Dovidio, Richard Gonzalez, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 16, 2019
Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer RiskChristine M Lusk, Angela S Wenzlaff, Donovan Watza, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2019
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)Anne S Tsao, Jieling Miao, Ignacio I Wistuba, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2016
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural MesotheliomaHarvey I Pass, Chandra Goparaju, Osvaldo Espin-Garcia, et al.Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 studyShirish Gadgeel, Glenwood Goss, Jean-Charles Soria, et al.The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.Patient Education and Counseling|January 12, 2017
Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologistsSusan Eggly, Lauren M Hamel, Tanina S Foster, et al.Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.Pageof 11